Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15050802 | 0.85 | GPR84 (0.61) | GPR84 | |
| SCHEMBL19337645 | 0.82 | GPR84 (0.70) | GPR84PDE4A | |
| SCHEMBL24800808 | 0.81 | GPR84 (0.59) | GPR84 | |
| SCHEMBL19337556 | 0.81 | GPR84 (0.69) | GPR84PDE4A | |
| SCHEMBL15826126 | 0.81 | GPR84 (0.85) | GPR84 | |
| SCHEMBL15051140 | 0.80 | GPR84 (1.00) | GPR84 | |
| SCHEMBL15051138 | 0.80 | GPR84 (1.00) | GPR84 | |
| SCHEMBL24800852 | 0.80 | GPR84 (0.64) | GPR84 | |
| SCHEMBL15051637 | 0.80 | GPR84 (1.00) | GPR84 | |
| SCHEMBL24282111 | 0.79 | GPR84 (0.74) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220499-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2022-01-11 | — | — | US | disclosed |
| US-20190002458-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GALAPAGOS NV (BE) | 2019-01-03 | — | — | US | disclosed |
| US-20180016275-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2018-01-18 | — | — | US | disclosed |
| US-20180016275-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2018-01-18 | — | — | US | disclosed |
| US-9708312-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists) | GALAPAGOS NV (BE) | 2017-07-18 | — | — | US | disclosed |
| US-9708312-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists) | GALAPAGOS NV (BE) | 2017-07-18 | — | — | US | disclosed |
| US-9708312-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists) | GALAPAGOS NV (BE) | 2017-07-18 | — | — | US | disclosed |
| EP-2935262-B1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2017-03-15 | — | — | EP | disclosed |
| EP-2935262-B1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160039807-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039807-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039807-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2016-02-11 | — | — | US | disclosed |
| EP-2935262-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | Galapagos NV (BE) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014095798-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014095798-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039807-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GPR84, GPR88, GPR65 | GPR84 1/4885PDE4A 489/4885 |
| US-20190002458-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GPR84, GPR88, GPR65 | GPR84 1/4885PDE4A 332/4885 |
| US-11220499-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GPR84, GPR88, GPR65 | GPR84 1/4885PDE4A 351/4885 |
| US-20180016275-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GPR84, GPR88, GPR65 | GPR84 1/4885PDE4A 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.